Base de dados : MEDLINE
Pesquisa : D27.505.696.560 [Categoria DeCS]
Referências encontradas : 953 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 96 ir para página                         

  1 / 953 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28928119
[Au] Autor:Jackson EK; Mi Z
[Ad] Endereço:Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania edj@pitt.edu.
[Ti] Título:8-Aminoguanosine Exerts Diuretic, Natriuretic, and Glucosuric Activity via Conversion to 8-Aminoguanine, Yet Has Direct Antikaliuretic Effects.
[So] Source:J Pharmacol Exp Ther;363(3):358-366, 2017 Dec.
[Is] ISSN:1521-0103
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:8-Aminoguanosine induces diuresis, natriuresis, glucosuria, and antikaliuresis. These effects could be mediated via 8-aminoguanosine's metabolism to 8-aminoguanine. In this study, we tested this hypothesis in anesthetized rats. First, we demonstrated that at 55- to 85-minutes post-i.v. administration, 8-aminoguanosine and 8-aminoguanine (33.5 mol/kg) significantly increased urine volume [ml/30 min: 8-aminoguanosine from 0.3 ± 0.1 to 0.9 ± 0.1 (mean ± S.E.M.; = 7); 8-aminoguanine from 0.3 ± 0.1 to 1.5 ± 0.2 ( = 8)], sodium excretion ( mol/30 min: 8-aminoguanosine from 12 ± 5 to 109 ± 21; 8-aminoguanine from 18 ± 8 to 216 ± 31), and glucose excretion ( g/30 min: 8-aminoguanosine from 18 ± 3 to 159 ± 41; 8-aminoguanine from 17 ± 3 to 298 ± 65). Both compounds significantly decreased potassium excretion ( mol/30 min: 8-aminoguanosine from 62 ± 7 to 39 ± 9; 8-aminoguanine from 61 ± 10 to 34 ± 6). Next, we administered 8-aminoguanosine and 8-aminoguanine i.v. (33.5 mol/kg) and measured renal interstitial (microdialysis probes) 8-aminoguanosine and 8-aminoguanine. The i.v. administration of 8-aminoguanosine and 8-aminoguanine similarly increased renal medullary interstitial levels of 8-aminoguanine [nanograms per milliliter; 8-aminoguanosine from 4 ± 1 to 1025 ± 393 ( = 6), and 8-aminoguanine from 2 ± 1 to 1069 ± 407 ( = 6)]. Finally, we determine the diuretic, natriuretic, glucosuric, and antikaliuretic effects of intrarenal artery infusions of 8-aminoguanosine and 8-aminoguanine (0.1, 0.3, and 1 mol/kg/min). 8-Aminoguanine increased urine volume and sodium and glucose excretion by the ipsilateral kidney, yet had only mild effects at the highest dose in the contralateral kidney. Intrarenal infusions of 8-aminoguanosine did not induce diuresis, natriuresis, or glucosuria in either the ipsilateral or contralateral kidney, yet decreased potassium excretion in the ipsilateral kidney. Together these data confirm that the diuretic, natriuretic, and glucosuric effects of 8-aminoguanosine are not direct, but require metabolism to 8-aminoguanine. However, 8-aminoguanosine has direct antikaliuretic effects.
[Mh] Termos MeSH primário: Diuréticos/farmacologia
Glicosúria/urina
Guanina/análogos & derivados
Guanosina/análogos & derivados
Hiperpotassemia/tratamento farmacológico
Natriuréticos/farmacologia
[Mh] Termos MeSH secundário: Animais
Diuréticos/metabolismo
Guanina/metabolismo
Guanina/farmacologia
Guanosina/metabolismo
Guanosina/farmacologia
Guanosina/uso terapêutico
Hiperpotassemia/metabolismo
Medula Renal/efeitos dos fármacos
Medula Renal/metabolismo
Masculino
Natriuréticos/metabolismo
Ratos Sprague-Dawley
Urodinâmica/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Diuretics); 0 (Natriuretic Agents); 12133JR80S (Guanosine); 28128-41-8 (8-aminoguanine); 3868-32-4 (8-aminoguanosine); 5Z93L87A1R (Guanine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170921
[St] Status:MEDLINE
[do] DOI:10.1124/jpet.117.243758


  2 / 953 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28641792
[Au] Autor:Greene SJ; Hernandez AF; Dunning A; Ambrosy AP; Armstrong PW; Butler J; Cerbin LP; Coles A; Ezekowitz JA; Metra M; Starling RC; Teerlink JR; Voors AA; O'Connor CM; Mentz RJ
[Ad] Endereço:Duke Clinical Research Institute, Durham, North Carolina; Division of Cardiology, Duke University Medical Center, Durham, North Carolina. Electronic address: stephen.greene@duke.edu.
[Ti] Título:Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.
[So] Source:J Am Coll Cardiol;69(25):3029-3039, 2017 Jun 27.
[Is] ISSN:1558-3597
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: It is unclear how patients hospitalized for acute heart failure (HF) who are long-term chronic HF survivors differ from those with more recent HF diagnoses. OBJECTIVES: The goal of this study was to evaluate the influence of HF chronicity on acute HF patient profiles and outcomes. METHODS: The ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial randomized 7,141 hospitalized patients with acute HF with reduced or preserved ejection fraction (EF) to receive nesiritide or placebo in addition to standard care. The present analysis compared patients according to duration of HF diagnosis before index hospitalization by using pre-specified cutoffs (0 to 1 month [i.e., "recently diagnosed"], >1 to 12 months, >12 to 60 months, and >60 months). RESULTS: Overall, 5,741 (80.4%) patients had documentation of duration of HF diagnosis (recently diagnosed, n = 1,536; >1 to 12 months, n = 1,020; >12 to 60 months, n = 1,653; and >60 months, n = 1,532). Across HF duration groups, mean age ranged from 64 to 66 years, and mean ejection fraction ranged from 29% to 32%. Compared with patients with longer HF duration, recently diagnosed patients were more likely to be women with nonischemic HF etiology, higher baseline blood pressure, better baseline renal function, and fewer comorbidities. After adjustment, compared with recently diagnosed patients, patients with longer HF duration were associated with more persistent dyspnea at 24 h (>1 to 12 months, odds ratio [OR]: 1.20; 95% confidence interval [CI]: 0.97 to 1.48; >12 to 60 months, OR: 1.34; 95% CI: 1.11 to 1.62; and >60 months, OR: 1.31; 95% CI: 1.08 to 1.60) and increased 180-day mortality (>1 to 12 months, hazard ratio [HR]: 1.89; 95% CI: 1.35 to 2.65; >12 to 60 months, HR: 1.82; 95% CI: 1.33 to 2.48; and >60 months, HR: 2.02; 95% CI: 1.47 to 2.77). The influence of HF duration on mortality was potentially more pronounced among female patients (interaction p = 0.05), but did not differ according to age, race, prior ischemic heart disease, or ejection fraction (all interactions, p ≥ 0.23). CONCLUSIONS: In this acute HF trial, patient profile differed according to duration of the HF diagnosis. A diagnosis of HF for ≤1 month before hospitalization was independently associated with greater early dyspnea relief and improved post-discharge survival compared to patients with chronic HF diagnoses. The distinction between de novo or recently diagnosed HF and worsening chronic HF should be considered in the design of future acute HF trials. (A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure; NCT00475852).
[Mh] Termos MeSH primário: Determinação de Ponto Final
Insuficiência Cardíaca/terapia
Hospitalização/estatística & dados numéricos
Peptídeo Natriurético Encefálico/administração & dosagem
Medição de Risco/métodos
[Mh] Termos MeSH secundário: Idoso
Progressão da Doença
Relação Dose-Resposta a Droga
Feminino
Seguimentos
Insuficiência Cardíaca/diagnóstico
Insuficiência Cardíaca/mortalidade
Mortalidade Hospitalar/tendências
Seres Humanos
Injeções Intravenosas
Masculino
Meia-Idade
Natriuréticos/administração & dosagem
Razão de Chances
Prognóstico
Estudos Prospectivos
Fatores de Risco
Taxa de Sobrevida/tendências
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Natriuretic Agents); 114471-18-0 (Natriuretic Peptide, Brain)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170816
[Lr] Data última revisão:
170816
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170624
[St] Status:MEDLINE


  3 / 953 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28490529
[Au] Autor:Rosenbaek JB; Al Therwani S; Jensen JM; Mose FH; Wandall-Frostholm C; Pedersen EB; Bech JN
[Ad] Endereço:University Clinic in Nephrology and Hypertension, Regional Hospital West Jutland and Aarhus University, Aarhus, Denmark; and jepros@rm.dk.
[Ti] Título:Effect of sodium nitrite on renal function and sodium and water excretion and brachial and central blood pressure in healthy subjects: a dose-response study.
[So] Source:Am J Physiol Renal Physiol;313(2):F378-F387, 2017 Aug 01.
[Is] ISSN:1522-1466
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Sodium nitrite (NaNO ) is converted to nitric oxide (NO) in vivo and has vasodilatory and natriuretic effects. Our aim was to examine the effects of NaNO on hemodynamics, sodium excretion, and glomerular filtration rate (GFR). In a single-blinded, placebo-controlled, crossover study, we infused placebo (0.9% NaCl) or 0.58, 1.74, or 3.48 µmol NaNO ·kg ·h for 2 h in 12 healthy subjects, after 4 days of a standard diet. Subjects were supine and water loaded. We measured brachial and central blood pressure (BP), plasma concentrations of renin, angiotensin II, aldosterone, arginine vasopressin (P-AVP), and plasma nitrite (P-[Formula: see text]), GFR by Cr-EDTA clearance, fractional excretion of sodium (FE ) free water clearance (C ), and urinary excretion rate of guanosine 3',5'-cyclic monophosphate (U-cGMP). The highest dose reduced brachial systolic BP (5.6 mmHg, = 0.003), central systolic BP (5.6 mmHg, = 0.035), and C (maximum change from 3.79 to 1.27 ml/min, = 0.031) and increased P-[Formula: see text] (from 0.065 to 0.766 µmol/l, < 0.001), while reducing U-cGMP (from 444 to 247 pmol/min, = 0.004). GFR, FE , P-AVP, and the components in the renin-angiotensin-aldosterone system did not change significantly. In conclusion, intravenous NaNO induced a dose-dependent reduction of brachial and central BP. The hemodynamic effect was not mediated by the renin-angiotensin-aldosterone system. NaNO infusion resulted in a vasopressin-independent decrease in C and urine output but no change in urinary sodium excretion or GFR. The lack of increase in cGMP accompanying the increase in [Formula: see text] suggests a direct effect of nitrite or nitrate on the renal tubules and vascular bed with little or no systemic conversion to NO.
[Mh] Termos MeSH primário: Pressão Arterial/efeitos dos fármacos
Artéria Braquial/efeitos dos fármacos
Taxa de Filtração Glomerular/efeitos dos fármacos
Rim/efeitos dos fármacos
Natriurese/efeitos dos fármacos
Natriuréticos/administração & dosagem
Doadores de Óxido Nítrico/administração & dosagem
Nitrito de Sódio/administração & dosagem
Micção/efeitos dos fármacos
Vasodilatadores/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Aquaporina 2/metabolismo
Biomarcadores/sangue
Estudos Cross-Over
GMP Cíclico/metabolismo
Relação Dose-Resposta a Droga
Canais Epiteliais de Sódio/metabolismo
Feminino
Voluntários Saudáveis
Seres Humanos
Rim/metabolismo
Masculino
Natriuréticos/metabolismo
Nitratos/metabolismo
Óxido Nítrico/metabolismo
Doadores de Óxido Nítrico/metabolismo
Nitritos/metabolismo
Sistema Renina-Angiotensina/efeitos dos fármacos
Método Simples-Cego
Nitrito de Sódio/metabolismo
Fatores de Tempo
Urodinâmica/efeitos dos fármacos
Vasodilatadores/metabolismo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (AQP2 protein, human); 0 (Aquaporin 2); 0 (Biomarkers); 0 (Epithelial Sodium Channels); 0 (Natriuretic Agents); 0 (Nitrates); 0 (Nitric Oxide Donors); 0 (Nitrites); 0 (SCNN1G protein, human); 0 (Vasodilator Agents); 31C4KY9ESH (Nitric Oxide); H2D2X058MU (Cyclic GMP); M0KG633D4F (Sodium Nitrite)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170512
[St] Status:MEDLINE
[do] DOI:10.1152/ajprenal.00400.2016


  4 / 953 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28332265
[Au] Autor:Kazi RN; Sattar MA; Johns EJ
[Ad] Endereço:College of Applied Medical Science, Prince Sattam Bin Abdul-Aziz University, Wadi Ad Dawaser, Saudi Arabia.
[Ti] Título:Antidiuretic and antinatriuretic response to high salt load in normotensive Wistar-Kyoto rats: Role of alpha-1A-adrenoreceptors.
[So] Source:Auton Autacoid Pharmacol;37(1):13-18, 2017 Jan.
[Is] ISSN:1474-8673
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Altered renal adrenergic responses have been recognized as pathophysiological responses to high salt intake. This study aims to investigate the influence of 6 weeks of high salt diet on α -adrenoceptor regulation of renal tubular antinatriuretic and antidiuretic response in normal Wistar Kyoto rats. To achieve the above objective, antinatriuretic and antidiuretic response to phenylephrine was measured in the absence and presence of 5-methylurapidil (5-MeU) using the inulin clearance method. Systemic mean arterial blood pressure and renal haemodynamics were also measured simultaneously. Six weeks of high salt intake in Wistar-Kyoto (WKY) rats did not bring any significant increase in mean arterial blood pressure. WKY rat on high salt diet (WKYHNa) showed an exaggerated increase in absolute and fractional sodium excretion. There was a significant involvement of α -adrenoceptor in carrying out renal tubular antinatriuretic and antidiuretic response in Wistar Kyoto rats on normal sodium diet (WKYNNa). However, α -adrenoceptor played a minimal role in handling the tubular reabsorptive response in WKY rats on high salt diet.
[Mh] Termos MeSH primário: Antidiuréticos/farmacologia
Natriuréticos/farmacologia
Receptores Adrenérgicos alfa 1/efeitos dos fármacos
Cloreto de Sódio na Dieta/farmacologia
[Mh] Termos MeSH secundário: Animais
Pressão Arterial/efeitos dos fármacos
Insulina/metabolismo
Masculino
Fenilefrina/farmacologia
Piperazinas/farmacologia
Ratos
Ratos Endogâmicos WKY
Circulação Renal
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antidiuretic Agents); 0 (Insulin); 0 (Natriuretic Agents); 0 (Piperazines); 0 (Receptors, Adrenergic, alpha-1); 0 (Sodium Chloride, Dietary); 1HLS600135 (5-methylurapidil); 1WS297W6MV (Phenylephrine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170718
[Lr] Data última revisão:
170718
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170324
[St] Status:MEDLINE
[do] DOI:10.1111/aap.12053


  5 / 953 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28284659
[Au] Autor:de Almeida CL; Boeing T; Somensi LB; Steimbach VM; da Silva LM; Andrade SF; Delle Monache F; Cechinel-Filho V; de Souza P
[Ad] Endereço:Programa de Pós-Graduação em Ciências Farmacêuticas, Núcleo de Investigações Químico-Farmacêuticas (NIQFAR), Universidade do Vale do Itajaí (UNIVALI), 88302-901 Itajaí, SC, Brazil.
[Ti] Título:Diuretic, natriuretic and potassium-sparing effect of nothofagin isolated from Leandra dasytricha (A. Gray) Cogn. leaves in normotensive and hypertensive rats.
[So] Source:Chem Biol Interact;268:103-110, 2017 Apr 25.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Active constituents from natural origin have long been used for the treatment of patients suffering from cardiovascular and renal diseases. This study therefore aimed to investigate the diuretic and natriuretic properties of nothofagin, a dihydrochalcone isolated from Leandra dasytricha (A. Gray) Cogn. leaves in normotensive and hypertensive rats. Male Wistar normotensive rats were orally treated with vehicle (1 ml/kg); hydrochlorothiazide (HCTZ; 25 mg/kg); ethyl acetate fraction from L. dasytricha (EALD; 3-30 mg/kg) and nothofagin (NOT; 0.3-3 mg/kg). Spontaneously hypertensive rats (SHR) received NOT (1 mg/kg), HCTZ (25 mg/kg) or vehicle. The cumulative diuretic index, urinary electrolytes excretion (Na and K ), pH, density and conductivity were measured at the end of the experiment (after 8 h). A7r5 and L929 cell lines were used to measure cell viability after exposure to NOT. Nitric oxide generation was quantified in A7r5 cell supernatant, and DPPH assay was used for evaluating the antioxidant properties of NOT. The urinary volume of normotensive rats were increased after the treatment with EALD, without any changes in Na or K excretion. NOT was able to induce diuresis and natriuresis, but not kaliuresis, in both normotensive and hypertensive rats. The reduction in prostanoids generation through cyclooxygenase inhibition, as well as the muscarinic receptor antagonism, fully avoided NOT-induced increases in diuretic index. NOT, which did not interfere with L929 or A7r5 cell viability, was able to stimulate nitric oxide generation in A7r5 cell, besides showing an antioxidant effect in scavenging the free-radical DPPH. Taken together, our study shows, for the first time, the diuretic, natriuretic and potassium-sparing effect of nothofagin in rats, which was associated with prostanoids generation, muscarinic receptor activation and antioxidant properties.
[Mh] Termos MeSH primário: Antioxidantes/uso terapêutico
Chalconas/uso terapêutico
Diurético Poupador de Potássio/uso terapêutico
Hipertensão/tratamento farmacológico
Melastomataceae/química
Natriuréticos/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Antioxidantes/isolamento & purificação
Antioxidantes/farmacologia
Linhagem Celular
Chalconas/isolamento & purificação
Chalconas/farmacologia
Diurético Poupador de Potássio/isolamento & purificação
Diurético Poupador de Potássio/farmacologia
Hidroclorotiazida/farmacologia
Hidroclorotiazida/uso terapêutico
Hipertensão/metabolismo
Hipopotassemia/prevenção & controle
Masculino
Camundongos
Natriuréticos/isolamento & purificação
Natriuréticos/farmacologia
Óxido Nítrico/metabolismo
Nitritos/metabolismo
Potássio/urina
Prostaglandinas/biossíntese
Ratos Wistar
Receptores Muscarínicos/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Chalcones); 0 (Diuretics, Potassium Sparing); 0 (Natriuretic Agents); 0 (Nitrites); 0 (Prostaglandins); 0 (Receptors, Muscarinic); 0 (nothofagin); 0J48LPH2TH (Hydrochlorothiazide); 31C4KY9ESH (Nitric Oxide); RWP5GA015D (Potassium)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170425
[Lr] Data última revisão:
170425
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170313
[St] Status:MEDLINE


  6 / 953 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27849656
[Au] Autor:Bronicki RA; Domico M; Checchia PA; Kennedy CE; Akcan-Arikan A
[Ad] Endereço:1Section of Pediatric Critical Care Medicine and Cardiology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX. 2Section of Pediatric Critical Care Medicine, Children's Hospital of Orange County, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA. 3Section of Pediatric Critical Care Medicine, Baylor College of Medicine, Texas Children's Hospital, Houston, TX. 4Section of Pediatric Critical Care Medicine and Nephrology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX.
[Ti] Título:The Use of Nesiritide in Children With Congenital Heart Disease.
[So] Source:Pediatr Crit Care Med;18(2):151-158, 2017 Feb.
[Is] ISSN:1529-7535
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: We evaluated the use of nesiritide in children with critical congenital heart disease, pulmonary congestion, and inadequate urine output despite conventional diuretic therapy. DESIGN: We conducted a retrospective analysis of 26 consecutive patients, comprising 37 infusions occurring during separate hospitalizations. Hemodynamic variables, urine output, and serum creatinine levels were monitored prior to and throughout the duration of therapy with nesiritide. In addition, the stage of acute kidney injury was determined prior to and throughout the duration of the therapy using a standardized definition of acute kidney injury-The Kidney Disease: Improving Global Outcomes criteria. SETTING: Cardiac ICU. PATIENTS: Pediatric patients with critical congenital heart disease, pulmonary congestion, and inadequate urinary output despite diuretic therapy. INTERVENTION: Nesiritide infusion. MEASUREMENTS AND MAIN RESULTS: The use of nesiritide was associated with a significant decrease in the central venous pressure and heart rate with a trend toward a significant increase in urine output. During the course of therapy with nesiritide, the serum creatinine and stage of acute kidney injury decreased significantly. The decrease in stage of acute kidney injury became significant by day 4 (p = 0.006) and became more significant with time (last day of therapy compared with baseline; p < 0.001). During 12 of the 37 infusions, the stage of acute kidney injury decreased by two or more (p < 0.001). CONCLUSIONS: Nesiritide had a favorable impact on hemodynamics and urine output in children with critical congenital heart disease and pulmonary congestion, and there was no worsening of renal function.
[Mh] Termos MeSH primário: Cardiopatias Congênitas/tratamento farmacológico
Natriuréticos/uso terapêutico
Peptídeo Natriurético Encefálico/uso terapêutico
[Mh] Termos MeSH secundário: Lesão Renal Aguda/diagnóstico
Lesão Renal Aguda/tratamento farmacológico
Lesão Renal Aguda/etiologia
Esquema de Medicação
Feminino
Cardiopatias Congênitas/complicações
Cardiopatias Congênitas/fisiopatologia
Frequência Cardíaca/efeitos dos fármacos
Seres Humanos
Lactente
Recém-Nascido
Infusões Intravenosas
Rim/efeitos dos fármacos
Rim/fisiopatologia
Masculino
Natriuréticos/farmacologia
Peptídeo Natriurético Encefálico/farmacologia
Oligúria/tratamento farmacológico
Oligúria/etiologia
Estudos Retrospectivos
Índice de Gravidade de Doença
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Natriuretic Agents); 114471-18-0 (Natriuretic Peptide, Brain)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161117
[St] Status:MEDLINE
[do] DOI:10.1097/PCC.0000000000000996


  7 / 953 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27766748
[Au] Autor:Díez J
[Ad] Endereço:Program of Cardiovascular Diseases, Centre for Applied Medical Research, and Department of Cardiology and Cardiac Surgery, University of Navarra Clinic, University of Navarra, Pamplona, Spain.
[Ti] Título:Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.
[So] Source:Eur J Heart Fail;19(2):167-176, 2017 Feb.
[Is] ISSN:1879-0844
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Natriuretic peptides (NPs) promote diuresis, natriuresis and vasodilation in early chronic heart failure (CHF), countering renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS) overstimulation. Despite dramatic increases in circulating NP concentrations as CHF progresses, their effects become blunted. Increases in diuresis, natriuresis, and vasodilation after administration of exogenous atrial (ANP) or brain (BNP) natriuretic peptides are attenuated in patients with advanced CHF compared with controls. Several major factors may account for the reduced effectiveness of the natriuretic peptide system (NPS) in CHF. First, there is reduced availability of active forms of NPs, namely BNP. Second, target organ responsiveness becomes diminished. Third, the counter-regulatory hormones of the RAAS and SNS, and endothelin-1 become over-activated. Therefore, pharmacological approaches to enhance the functional effectiveness of the NPS in CHF have been explored in recent years. In terms of clinical outcomes, studies of synthetic BNP, or of neprilysin inhibitors alone or associated with an angiotensin converting enzyme inhibitor, have been controversial for several reasons. Recently, however, encouraging results have been obtained with the angiotensin receptor neprilysin inhibitor sacubitril/valsartan. The available data show that treatment with sacubitril/valsartan is associated with increased levels of NPs and their intracellular mediator cyclic guanosine monophosphate, suggesting improved functional effectiveness of the NPS, in addition to beneficial effects on mortality and morbidity outcomes. Therefore, combined targeting of the NPS and RAAS with sacubitril/valsartan emerges as the current optimal approach for redressing the neurohormonal imbalance in CHF.
[Mh] Termos MeSH primário: Fator Natriurético Atrial/metabolismo
Endotelina-1/metabolismo
Insuficiência Cardíaca/metabolismo
Peptídeo Natriurético Encefálico/metabolismo
Sistema Renina-Angiotensina
[Mh] Termos MeSH secundário: Aminobutiratos/uso terapêutico
Antagonistas de Receptores de Angiotensina/uso terapêutico
Doença Crônica
Insuficiência Cardíaca/tratamento farmacológico
Insuficiência Cardíaca/fisiopatologia
Seres Humanos
Natriuréticos/uso terapêutico
Peptídeo Natriurético Encefálico/uso terapêutico
Neprilisina/antagonistas & inibidores
Receptores do Fator Natriurético Atrial/metabolismo
Sistema Nervoso Simpático/fisiopatologia
Tetrazóis/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Aminobutyrates); 0 (Angiotensin Receptor Antagonists); 0 (Endothelin-1); 0 (LCZ 696); 0 (Natriuretic Agents); 0 (Tetrazoles); 114471-18-0 (Natriuretic Peptide, Brain); 85637-73-6 (Atrial Natriuretic Factor); EC 3.4.24.11 (Neprilysin); EC 4.6.1.2 (Receptors, Atrial Natriuretic Factor); EC 4.6.1.2 (atrial natriuretic factor receptor A); EC 4.6.1.2 (atrial natriuretic factor receptor B); EC 4.6.1.2 (atrial natriuretic factor receptor C)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161022
[St] Status:MEDLINE
[do] DOI:10.1002/ejhf.656


  8 / 953 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27738973
[Au] Autor:Martin-Cano FE; Caso-Agundez M; Camello-Almaraz C; Santos FJ; Espin MT; Madrid JA; Diez-Perez A; Camello PJ; Pozo MJ
[Ad] Endereço:Department of Physiology, Faculty of Nursing and Occupational Therapy, University of Extremadura, 10003, Caceres, Spain.
[Ti] Título:Octodon degus, a new model to study the agonist and plexus-induced response in the urinary bladder.
[So] Source:J Physiol Biochem;73(1):77-87, 2017 Feb.
[Is] ISSN:1877-8755
[Cp] País de publicação:Spain
[La] Idioma:eng
[Ab] Resumo:Urinary bladder function consists in the storage and controlled voiding of urine. Translational studies require animal models that match human characteristics, such as Octodon degus, a diurnal rodent. This study aims to characterize the contractility of the detrusor muscle and the morphology and code of the vesical plexus from O. degus. Body temperature was measured by an intra-abdominal sensor, the contractility of detrusor strips was evaluated by isometric tension recording, and the vesical plexus was studied by electrical field stimulation (EFS) and immunofluorescence. The animals showed a diurnal chronotype as judged from core temperature. The myogenic contractile response of the detrusor muscle to increasing doses of KCl reached its maximum (31.04 mN/mm ) at 60 mM. In the case of cumulative dose-response of bethanecol, the maximum response (37.42 mN/mm ) was reached at 3.2 × 10 M. The response to ATP was clearly smaller (3.8 mN/mm ). The pharmacological dissection of the EFS-induced contraction identified ACh and sensory fibers as the main contributors to this response. The neurons of the vesical plexus were located mainly in the trigone area, grouped in big and small ganglia. Out of them, 48.1 % of the neurons were nitrergic and 62.7 % cholinergic. Our results show functional and morphological similarities between the urinary bladder of O. degus and that of humans.
[Mh] Termos MeSH primário: Contração Muscular/efeitos dos fármacos
Músculo Liso/efeitos dos fármacos
Músculo Liso/inervação
Octodon/fisiologia
Bexiga Urinária/efeitos dos fármacos
Bexiga Urinária/inervação
[Mh] Termos MeSH secundário: Trifosfato de Adenosina/metabolismo
Animais
Betanecol/farmacologia
Temperatura Corporal
Neurônios Colinérgicos/citologia
Neurônios Colinérgicos/efeitos dos fármacos
Neurônios Colinérgicos/metabolismo
Neurônios Colinérgicos/fisiologia
Estimulação Elétrica
Técnica Indireta de Fluorescência para Anticorpo
Gânglios/anatomia & histologia
Gânglios/efeitos dos fármacos
Gânglios/metabolismo
Gânglios/fisiologia
Seres Humanos
Técnicas In Vitro
Masculino
Agonistas Muscarínicos/farmacologia
Músculo Liso/metabolismo
Músculo Liso/fisiologia
Natriuréticos/farmacologia
Neurônios Nitrérgicos/citologia
Neurônios Nitrérgicos/efeitos dos fármacos
Neurônios Nitrérgicos/metabolismo
Neurônios Nitrérgicos/fisiologia
Octodon/anatomia & histologia
Cloreto de Potássio/farmacologia
Especificidade da Espécie
Bexiga Urinária/metabolismo
Bexiga Urinária/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Muscarinic Agonists); 0 (Natriuretic Agents); 004F72P8F4 (Bethanechol); 660YQ98I10 (Potassium Chloride); 8L70Q75FXE (Adenosine Triphosphate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171111
[Lr] Data última revisão:
171111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161015
[St] Status:MEDLINE
[do] DOI:10.1007/s13105-016-0527-z


  9 / 953 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27727024
[Au] Autor:Yao Y; Davis G; Harrison JC; Walker RJ; Sammut IA
[Ad] Endereço:Departments of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.
[Ti] Título:Renal functional responses in diabetic nephropathy following chronic bilateral renal denervation.
[So] Source:Auton Neurosci;204:98-104, 2017 May.
[Is] ISSN:1872-7484
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Renal innervation operates in conjunction with the intrarenal renin-angiotensin system (RAS) to control tubular reabsorption of sodium and water. This relationship remains unexplored in diabetic nephropathy. This study investigates the effects of acute RAS inhibition and chronic renal denervation on renal function in diabetic rats. Diabetes was induced in mRen-2 rats prior to conducting chronic bilateral denervation in diabetic and normoglycaemic animals. At 12-weeks post-diabetic induction, renal haemodynamics and tubular handling of sodium and water were measured before and after acute captopril infusion. Neither GFR nor renal blood flow were affected by diabetes or chronic renal denervation alone. While captopril produced natriuretic and diuretic responses in chronically-denervated diabetic animals, shown by increases (P<0.05) of 38±14% in absolute (U V), and 71±20% in fractional sodium excretion (FE ), and 68±17% in urine volume (UV); in the innervated-diabetic group captopril produced anti-natriuretic effects (U V and FE reduced by 41±10% and 29±13%, respectively; all P<0.05). This difference was not observed however in normoglycaemic groups where RAS inhibition produced anti-natriuretic (normoglycaemic denervated vs. innervated: 56±14% vs. 49±14% U V; 45±13% vs. 37±14% FE ) and anti-diuretic (normoglycaemic-denervated vs. innervated: 34±8% vs. 38±10% UV) effects in both denervated and innervated animals. These data indicate that renal neuronal control is altered in chronic hyperglycaemia. The role of the RAS in sodium conservation in the diabetic kidney, appears to be more significant in the absence of renal innervation, suggesting that the interaction between the RAS and renal sympathetic nervous system is responsible for changes in renal function in diabetic nephropathy.
[Mh] Termos MeSH primário: Nefropatias Diabéticas/fisiopatologia
Rim/inervação
Rim/fisiopatologia
Sistema Renina-Angiotensina/fisiologia
Sistema Nervoso Simpático/fisiopatologia
[Mh] Termos MeSH secundário: Animais
Pressão Sanguínea/efeitos dos fármacos
Pressão Sanguínea/fisiologia
Captopril/farmacologia
Denervação
Diabetes Mellitus Experimental/tratamento farmacológico
Diabetes Mellitus Experimental/fisiopatologia
Nefropatias Diabéticas/tratamento farmacológico
Feminino
Taxa de Filtração Glomerular/efeitos dos fármacos
Taxa de Filtração Glomerular/fisiologia
Frequência Cardíaca/efeitos dos fármacos
Frequência Cardíaca/fisiologia
Rim/irrigação sanguínea
Rim/efeitos dos fármacos
Natriuréticos/farmacologia
Distribuição Aleatória
Ratos Transgênicos
Circulação Renal/efeitos dos fármacos
Circulação Renal/fisiologia
Sistema Renina-Angiotensina/efeitos dos fármacos
Sistema Nervoso Simpático/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Natriuretic Agents); 9G64RSX1XD (Captopril)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161012
[St] Status:MEDLINE


  10 / 953 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26164026
[Au] Autor:Kong LG; Wang CL; Zhao D; Wang B
[Ad] Endereço:Departments of 1Cardiovascular Medicine, 2Nursing and 3Pathology, The Second Clinical Medical School of Inner Mongolia University for the Nationalities, Inner Mongolia Forestry General Hospital, Yakeshi, China.
[Ti] Título:Nesiritide Therapy Is Associated With Better Clinical Outcomes Than Dobutamine Therapy in Heart Failure.
[So] Source:Am J Ther;24(2):e181-e188, 2017 Mar/Apr.
[Is] ISSN:1536-3686
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To evaluate the therapeutic effects of dobutamine and nesiritide in the treatment of heart failure (HF), a meta-analysis of published studies was conducted. Computerized bibliographic databases in Chinese and English languages were carefully searched to identify the relevant literature. A total of 6 cohort studies were enrolled in current meta-analysis for statistical analyses. The effect of dobutamine and nesiritide in patients with HF was estimated by odds ratios (ORs) and 95% confidence interval (CI). Our results revealed a significantly higher survival rate in nesiritide-treated patients, compared with those treated with dobutamine (OR = 1.97; 95% CI, 1.43-2.71; P < 0.001). In addition, a lower readmission rate was also associated with the nesiritide-treated group in comparison with the dobutamine-treated group (OR = 1.96; 95% CI, 1.39-2.78; P < 0.001). A stratified analysis revealed that the subgroup of patients with HF treated with nesiritide showed higher survival outcomes than those patients with HF treated with dobutamine when follow-up period was greater than 6 months (OR = 1.70; 95% CI, 1.21-2.38; P = 0.002) but not under 6 months (P > 0.05). This indicated that nesiritide treatment had longer term benefits as well. Interestingly, based on the reason for readmission, a subgroup analysis of the HF subgroup and the "all-cause" subgroup showed that higher readmission rates were associated with dobutamine treatment in both subgroups (HF: OR = 2.71; 95% CI, = 1.51-4.83; P = 0.001; all-cause: OR = 1.64; 95% CI, 1.06-2.53; P = 0.026; respectively). Our results suggest that nesiritide therapy is associated with a lower in-hospital mortality rates and decreased readmission rates compared with dobutamine treatment in patients with HF.
[Mh] Termos MeSH primário: Cardiotônicos/uso terapêutico
Dobutamina/uso terapêutico
Insuficiência Cardíaca/tratamento farmacológico
Natriuréticos/uso terapêutico
Peptídeo Natriurético Encefálico/uso terapêutico
[Mh] Termos MeSH secundário: Insuficiência Cardíaca/mortalidade
Mortalidade Hospitalar
Seres Humanos
Razão de Chances
Readmissão do Paciente
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Cardiotonic Agents); 0 (Natriuretic Agents); 114471-18-0 (Natriuretic Peptide, Brain); 3S12J47372 (Dobutamine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170314
[Lr] Data última revisão:
170314
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150713
[St] Status:MEDLINE
[do] DOI:10.1097/MJT.0000000000000278



página 1 de 96 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde